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Background: Non-hereditary angioedema (non-HAE) is characterized by local swelling due to self-limiting, subcutaneous
or submucosal extravasation of fluid, and can be divided into three subtypes. These subtypes are believed to have
different pathophysiological backgrounds and are referred to in recent guidelines as bradykinin-mediated (e.g. caused by
angiotensin-converting-enzyme-inhibitors), mast cell-mediated (e.g. angioedema with wheals) or idiopathic (cause
unknown). Bradykinin-mediated subtypes are more closely related to hereditary angioedema than the other forms.
Because clinical features of these non-HAE subtypes have not been studied in detail, we have looked at the clinical
characteristics of symptoms and potential differences in clinical presentation of bradykinin-mediated and mast cell-
mediated angioedema (AE) subtypes.
Methods: A questionnaire was sent to patients presenting with AE at our tertiary outpatient clinic to document clinical
characteristics, potential triggers and location of AE. The severity of AE attacks was analysed using visual analogue
scales (VAS).
Results: The questionnaire was returned by 106 patients, of which 104 were included in the analysis. AE with
wheals, idiopathic AE, and drug-associated AE occurred in 64 (62%), 25 (24%) and 15 patients (14%) respectively.
Most patients (62%) reported prodromal symptoms while 63% reported multiple locations for an attack. Face and
oropharynx were the main locations of AE attacks of any subtype while swelling was the symptom most frequently
reported as severe. Overall severity of the last attack was indicated as severe by 68% of the patients. There were no
differences between the subgroups.
Conclusion: This similarity in clinical presentation raises the possibility that ACEi-induced, mast cell-mediated and
idiopathic AE share common pathways.
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Angioedema (AE) is caused by a rapid local increase in
permeability of capillaries and venules with subsequent
extravasation of fluid into the interstitial space, which
becomes clinically manifest as self-limiting, localized
subcutaneous or submucosal swellings. AE is classified
into several subtypes [1-3]. The first step in the* Correspondence: melzen3@umcutrecht.nl
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unless otherwise stated.classification is to differentiate AE with wheals from AE
without wheals. AE with wheals can be diagnosed as
chronic spontaneous urticaria (CSU) or chronic indu-
cible urticaria (CINDU), and is presumably mast-cell
mediated [2], although treatment with (high doses of )
antihistamines does not always lead to complete symp-
tom relief [4]. AE may occur in all forms of CSU and
CINDU, except dermographism [3]. It can be caused or
aggravated by medical drugs such as NSAIDs and antibi-
otics [2,5]. AE without wheals can be classified further
into hereditary and acquired types. Both can be caused
by a C1-inhibitor deficiency, in which case a diagnosis ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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AAE) can be made. HAE can subsequently be divided in
to three types, C1-INH-HAE types I and II caused by C1
inhibitor deficiency and hereditary AE with factor XII
mutations or of unknown origin (formerly known as
type III HAE), which causes enhanced generation of
bradykinin [1,6].
AE without wheals can also be associated with the use
of angiotensin-converting-enzyme-inhibitors (ACEi). ACEi
causes AE which is presumably bradykinin-mediated and
is more closely related to hereditary angioedema (HAE)
than the other forms [6]. Finally, idiopathic AE is diag-
nosed when all other causes have been excluded [2-6].
Idiopathic AE can be either histaminergic or non-
histaminergic, based on the response to antihistamines [6].
It is unclear to what extent idiopathic AE has a similar
pathogenesis to angioedema in patients suffering with
chronic spontaneous urticaria (CSU).
Clinical characteristics for HAE are well-described in
previous literature [1,7]. For non-HAE however, symp-
toms and clinical impact are not well described. In this
study, a large unselected group of non-HAE patients
was categorized into the three AE subtypes: AE with
wheals (mast-cell mediated), ACEi-induced AE (bradyki-
nin-mediated) and idiopathic AE (unknown cause). The
clinical characteristics, locations and impact of the dis-
ease for each subtype were documented. In addition, we
adapted the VAS tools developed for HAE and supple-
mented them with extra symptom scores, and used these
to assess severity and type of symptoms of the last AE
attack in these patients [8,9].Methods
Patients
All patients visiting the outpatient clinic of the Department
of Dermatology and Allergology of the UMC Utrecht
between October 2007 and December 2010 for evalu-
ation of angioedema were selected. The diagnosis AE
was based on a history of bouts of mucocutaneous or
subcutaneous swellings. All case records were checked
by one of the investigators to verify the diagnosis. Ex-
clusion criteria were (a) decreased C4-value or proven
HAE or AAE due to C1-inhibitor deficiency; (b) pa-
tients known to have comorbid malignancy requiring
active treatment, because we wanted to avoid any un-
necessary discomfort for patients with this disease; and
(c) incapability of a patient to fill out the questionnaire.
Four patients with AE were excluded from the study
because they met one of these criteria, 2 with malig-
nancy, 1 with a cerebrovascular accident and 1 with
psychiatric disease.
This study was approved by the ethics committee of
the UMC Utrecht, protocol number 13-241/C.Questionnaires
Questionnaires were sent to all selected patients to
evaluate the subtype and characteristics of their AE. A
written reminder was sent to patients who failed to reply
after 2 weeks. Two weeks after the first reminder pa-
tients who had still failed to respond were contacted by
phone and asked to complete the questionnaire. Of the
165 patients to whom the questionnaire was sent, 106
(64%) returned it. One patient did not meet inclusion
criteria and the remaining 105 patients were included in
the study. Reasons for not filling out the questionnaire
included: lack of time (n = 15), lack of a recent AE attack
(n = 16), as ascertained during a phone interview, or
were unknown (n = 28).
Evaluation of symptoms and locations
The questionnaire consisted of 17 general questions re-
lated to the frequency and impact on daily life, locations
involved and treatment of AE attacks. The question-
naires were provided with images to mark the location
(s) involved during the last attack. We elected to evalu-
ate the last attack rather than, for instance, the most se-
vere one in order to minimise recall bias. Moreover, we
restricted the analysis to patients who had visited the
clinic within the recruitment period. In addition, the
questionnaire was designed in such a way that answers
were double-checked whenever possible. For example,
location of the last attack by questionnaire was verified
by asking patients to indicate this location also on
graphs.
Severity of symptoms
Furthermore the questionnaire contained a series of
symptom-specific visual analogue scale (VAS) [6,7] to
assess the severity of the last attack of AE. A value
of <20 mm was considered to represent a symptom or
attack of minimal severity, >20 mm-50 mm a moderate
symptom or attack, and >50 mm a severe symptom or
attack. Different sets of VAS [7] were used and expanded
for different anatomical locations of an AE attack;
namely the face (eyelids, cheeks, lips and ears), the oro-
pharyngeal cavity (tongue, throat, uvula and vocal cords),
the extremities (arms, hands, legs, feet and trunk (also
referred to as peripheral locations) and the abdomen.
Subtyping of AE
The following, clinically defined, subgroups of AE
were discriminated in patients who had completed the
questionnaire:
1) AE associated with wheals, (AE with wheals):
Patients were included in this category when they
had associated wheals or pruritus alone or if they
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a relation with NSAID or ACEi use they were
considered to be drug-associated (see next
subgroup).
2) AE associated with the use of drugs as NSAID,
antibiotics or ACEi: Patients were included in this
category when AE became manifest for the first
time after using these drugs. As we did not identify
patients with AE induced by NSAIDs or antibiotics,
this subgroup is further referred to as ACEi-
induced AE.
3) AE associated with other diseases such as auto-
immune disease: This category is further referred to
as AE due to other causes. After subtyping, this
subgroup resulted in only one patient with AE related
to food exposure, who was excluded from further
analysis as the group was not sufficiently large to
produce statistically reliable results.
4) Idiopathic AE was diagnosed when no other cause
for AE could be identified.Data management
Differences between the different subgroups were evalu-
ated by analyzing the answers to the general questions
in the questionnaire and the VAS scores of the last AE
attack. The VAS forms were used to assess the location
as well as the severity and type of symptoms. Analysis of
the time to 50% reduction and to minimal symptoms of
the last attack was carried out using the answers to that
specific question.
All patients who completed and returned the question-
naire were allocated to subgroups. After exclusion of the
patient in the group of AE due to other causes, the final
number of patients, 104 in total, were included in the
analysis. Descriptive statistics were used to describe the
data. The data was presented as median values with
interquartile ranges.Results
Patient characteristics and subtypes of AE
The median age of the 104 patients included in the
study was 55 years and 67 (64%) were female. Theble 1 Clinical characteristics of nonHAE patients (n-104)
Total group n = 104 Idiopathic n-
ale (%) 37 (36%) 14 (56
e (years) 55 (42–65) 61 (44
mily history with AE 12 (12%) 1 (4%
mily history unknown 15 (14%) 4 (16
e of onset 46 (35–60) 47 (36
ta is presented as numbers and percentages or median values with interquartilemedian age of onset of AE was 46 years. 12 patients had
a positive family history of AE, but none had a proven
C1-inhibitor deficiency. 64 patients (62%) had AE with
wheals, 15 (14%) had ACEi-induced AE, and 25 (24%)
had idiopathic AE. Demographic data of the different
subgroups is listed in Table 1.Locations of AE attacks
All reported locations are shown in Figure 1a. In all sub-
groups, the face was mentioned most frequently as a lo-
cation of attacks (96 [92%]). The second most frequent
location for all subgroups was the oropharynx (68
[65%]). 47 (45%) mentioned a previous peripheral attack.
10 (10%) mentioned at least one attack in the genital lo-
cation, and 20 (19%) reported at least one attack in the
abdominal location. Figure 1b shows a breakdown of the
frequency of facial attacks and Figure 1c shows a break-
down of the frequency of oropharyngeal locations of AE
attacks. The lips are the most frequently involved loca-
tion in the face, while the ears are the least involved. No
patients in the idiopathic AE subgroup reported an at-
tack of the ears. The tongue and pharynx were the most
frequent locations of attacks in the oropharynx, with
49% and 35% of all patients suffering with attacks at
these locations, respectively. Laryngeal attacks occurred
in 13% of patients. Laryngeal locations were less fre-
quent in the idiopathic AE subgroup (1 patient (4%) with
idiopathic AE) as compared to 15% for AE with wheals
and 20% with ACEi-induced AE. In ACEi-induced AE,
uvular locations were less frequent (7%) compared to
idiopathic AE (16%) and AE with wheals (25%). All dif-
ferent anatomical locations involved in at least one his-
torical attack mentioned by the patients are shown in
Additional file 1.
Sixty-six of the 104 patients (63%) reported that they
had suffered AE attacks at multiple locations. Patients
with idiopathic AE reported this less frequently (up to
40% of all attacks were at multiple locations) than the
other groups. Characteristics of angioedema attacks are
summarized in Table 2. 62% of the patients reported
prodromal symptoms preceding an attack of AE. This
included paraesthesia, pruritus or erythema. Only 40% of25 AE with wheals n = 64 ACEi-induced n-15
%) 15 (23%) 8 (53%)
–67) 50 (40–61) 64 (58–67)
) 11 (17%) 0 (0%)
%) 7 (11%) 4 (27%)
–61) 41 (33–54) 59 (63)
ranges.
Figure 1 Locations of AE attacks. Reported locations of attacks for the total group (n = 104) and by subtype of angioedema for all locations,
presented as percentages (a). A breakdown of facial (b) and oropharyngeal attacks (c) is also presented. The exact numbers of all locations, by
subtype, are available as additional file.
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Table 2 Characteristics of non-HAE attacks per patient
(n = 104)





Multiple locations 66 (63)











<1 per year 14 (13)*
>1 per year but <1x per month 37 (36)
>1 per month but <1x per week 21 (20)
>1 per week 19 (18)
Daily 4 (4)
Unknown 9 (9)
*Data is presented as numbers and percentages; **data presented as
median hours.
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symptoms (n = 6, of which n = 3 reported pruritus).
High severity and long duration of the last AE attack
VAS scores for the last AE attack were completed by 99
of the 104 patients. 67 (68%) rated the overall severity of
the last attack as ≥50 mm on VAS for at least one in-
volved location. For facial and oropharyngeal locations,
swelling was the most frequent symptom reported as ≥
50 mm (Figure 2a and b). In addition, many patients
with oropharyngeal AE reported severe (VAS ≥50 mm)
difficulties in swallowing (55%), severe changes in speech
(41%) and severely impaired breathing (37%). Pruritus
and swelling were the symptoms most frequently scored
severe for peripheral AE (Figure 2c). Ten patients with
peripheral AE also reported severe pain , but this was
not reported by idiopathic AE with peripheral locations.
VAS scores did not differ between AE subgroups for
oropharyngeal attacks. Median time to 50% resolution
was 23 hours for facial attacks, 15 hours for oropharyn-
geal attacks, 30 hours for peripheral attacks, and 9 hours
for abdominal attacks (Table 2). Median time to completeresolution was 57 hours for facial lesions, 38 hours for
oropharyngeal attacks, 66.6 hours for peripheral attacks,
and 33 hours for abdominal attacks.
Impact of AE attacks on daily life
Of the total group, a minority showed to have a high fre-
quency of attacks: 20 patients (19%) reported having suf-
fered an attack more than once a week, 23 (22%) more
than once a month, 32 (31%) more than once a year, and
22 patients (21%) less than once a year. The frequency
of attacks was comparable in most subgroups except
that, compared to other subgroups, in the idiopathic
group more patients reported having suffered an attack
less than once a year (32% versus 17-20%, respectively).
Medical burden and social impact on daily life of hav-
ing AE are summarized in Table 3. Of all 104 patients,
22 (21%) reported having sought medical advice when
suffering with an AE attack. Twenty-nine patients (28%)
reported having been admitted to the hospital at least
once because of an AE attack of which 5 (5%) had been
admitted to an Intensive Care Unit at least once. A ma-
jority of the patients (77%) reported having used antihis-
tamines on demand during an AE attack. Especially in
AE with wheals, oral corticosteroids were used on de-
mand as well. Sixty-one (59%) used antihistamines as
prophylactic medication, 29 patients (28%) reported
prophylactic use of oral corticosteroids to prevent at-
tacks of swelling.
Three of 104 patients (3%) reported having been ab-
sent from work or school because of an AE attack more
than once a week, 5% more than once a month, 19
(18%) more than once a year and 61 (59%) less than
once a year. 15 could not be evaluated in this respect
since they neither had a job nor went to school. Surpris-
ingly, absenteeism was seen mostly in patients with a
lower attack frequency, possibly indicating that patient
with frequent symptoms accept symptoms to some
extent.
Discussion
To our knowledge, this is the first study to describe in
detail the characteristics of angioedema attacks in a large
group of non-hereditary angioedema patients, and to
study potential differences between clinical subtypes. In
contrast to previous literature [10], we also included in-
formation of patients suffering with AE in the presence
of wheals. It has been suggested previously that angio-
edema resulting from bradykinin release and resulting
from mast cell mediator release might show similar signs
and symptoms [2,11]. In this study we show that clinical
manifestations of attacks in patients with non-HAE sub-
types are indeed remarkably similar in locations, fre-
quency and severity of attacks. Our 104 patients could
be allocated to the following, clinically relevant subtypes
Figure 2 Symptoms per location of AE attacks. Symptoms of the last angioedema attack of each patient reported to be severe for facial (a),
oropharyngeal (b) and peripheral locations (c). Percentages on the Y-axis represent the percentage of patients that reported the indicated
symptom VAS score as ≥50 mm. Note that the number of patients varies between the different locations because the location of the last attack
differs between patients.
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AE due to other causes (n = 2, both excluded from ana-
lysis) and idiopathic AE (n = 25). Of these subtypes, AE
with wheals is believed to be mast cell-mediated, idio-
pathic AE may be either mast cell-or bradykinin-
mediated and ACEi-associated AE is believed to be
bradykinin-mediated. Beltrami et al. reported on 111
patients with ACE-inhibitor angioedema. After discon-
tinuation of the ACE inhibitor, 46% of patients had fur-
ther recurrences of angioedema, although less-frequent.
These findings suggest that ACE inhibitors may certainly
exacerbate angioedema in a large subset of patients but
may not be the sole cause of angioedema [12].All patients reporting pruritus, itching of AE lesions or
presence of both AE and wheals, were allocated to the
AE with wheals subgroup when they did not use ACEi
or NSAIDs. In drug-associated AE, ACEi, antibiotics and
NSAIDs are commonly known culprits [13]. It is argu-
able that NSAID-induced AE and ACEi-induced AE
should be combined in a single subtype, as the first
seems to be mast cell mediated and the latter bradykinin
mediated. In our study this has no effects on the data as
there were no patients included with AE triggered by
NSAIDs. This classification is based on etiological fea-
tures. It is deliberately not based on biochemical mecha-
nisms because of a lack of evidence on this topic. These










Seek medical advice Yes 22(21) 13(20) 7(28) 2(13)
Unknown 4(4) 2(3) 2(8) 0(0)
Angioedema-related admission To hospital 29(28) 19(30) 5(20) 5(33)
To ICU 5(5) 2(3) 2(8) 1(7)
Social impact
AE-related absenteeism <1 per year 60(58) 36(53) 16(64) 10(67)
>1x per year but <1x per month 19(18) 12(19) 6(24) 1(7)
>1x per month but <1x per week 5(5) 4(6) 1(4) 0(0)
>1x per week 3(3) 3(5) 0 0
Not applicable 15(15) 9(14) 2(8) 3(20)
Unknown 2(2) 2(3) 0(0) 1(7)
*Data are presented as numbers and percentages: n (%).
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though different classifications are sometimes used [14].
We did not find striking differences among the demo-
graphic parameters of AE subtypes, except for a higher
median age of ACEi-induced AE. This finding most
likely reflects the fact that patients taking medication,
especially antihypertensive drugs, are generally older.
The majority of our patients (62%) reported prodromal
symptoms whereas in previous surveys among HAE pa-
tients even higher percentages ranging from 82.5-95.7%
were reported [15]. Strikingly, 50% of the reported pro-
dromal symptoms in ACEi-induced AE consisted of
pruritus, which would not be expected for a bradykinin-
mediated swelling. Our study was not designed to deter-
mine the interval between the reported prodromal
symptoms and the onset of angioedema. To our know-
ledge, no study has been performed to measure pro-
dromal symptoms in chronic urticaria patients. Also, a
majority of patients reported involvement of multiple lo-
cations during attacks (63%). Face and oropharynx were
the most frequent locations. AE attacks involving the
extremities had the longest resolution time (almost
67 hours). We did not find gross differences in involved
locations and symptoms among the various AE subtypes.
For all subtypes most AE attacks occur in the face and
in the oropharynx, which is consistent with recent pub-
lished literature [16]. In HAE due to C1-inhibitor defi-
ciency, extremities and the gastrointestinal tract are
preferred locations [9,17-20]. In contrast, in HAE with
normal C1 inhibitor [21], attacks also occur most fre-
quently in face and oropharynx. One may therefore
speculate that C1-inhibitor deficiency per se influences
the location of AE attacks, though the molecular mech-
anism to explain this effect of C1-inhibitor is far from
clear. Another option is that in non-HAE, abdominalattacks are not as well recognized as in HAE leading to
underreporting.
63% of the patients reported lesions on multiple loca-
tions during a single attack. Such a high frequency of
multiple locations has also recently been reported in a
study on peripheral attacks of HAE [9]. This might indi-
cate that AE attacks result from a systemic trigger, rather
than a local activation process. However, it cannot be ex-
cluded that local activation of biochemical processes oc-
curs at multiple sites at the same moment. This is one
of the topics in angioedema that should be explored fur-
ther in future research.
Our study is retrospective in nature and therefore may
have limitations due to recall bias. We tried to minimize
this (as described in the methods section of this article),
however the recall period of 5 years is rather long. In
the vast majority of patients (83%), the last attack was
reported less than two years in the past. Another limi-
tation is the number of missing values of C1-INH or
C4. For idiopathic AE, blood test results were missing
in 58% of patients, for AE with wheals this was the case
in 48% of the patients. However, in all patients where
blood tests were performed, the test results were nega-
tive. We suspect this had only a limited impact on our
results.
Furthermore, patients reporting pruritis were allocated
to the subgroup AE with wheals. However, pruritis was
also reported as a prodromal symptom. It may be diffi-
cult to separate pruritus as a prodromal symptom from
pruritus as a symptom in patients with wheals. This
could lead to overestimation of the AE subtype with
wheals. Additionally, the ACEi-induced AE group may
be underestimated due to missing values in the medical
records, causing a possible overestimation of the idio-
pathic AE group. We think this had limited impact on
Schulkes et al. Clinical and Translational Allergy  (2015) 5:5 Page 8 of 9our conclusions since no major differences were ob-
served between the subgroups.
VAS scoring provides a sensitive, reliable and validated
tool for evaluation of patient reported outcome mea-
sures such as pain [22-25]. We used VAS scoring to as-
sess severity of pain as well as that of other symptoms of
the AE attacks. This analysis revealed that swelling is the
dominant symptom of AE independent of subtype. Strik-
ingly, the patients reported a high proportion (69%) of
severe attacks. There is literature that suggests that VAS
scores can be obtained retrospectively. In a previous
study, VAS-scores were validated as an instrument for
measuring HAE attack severity. VAS scores were ob-
tained retrospectively. HAE patients reported VAS scores
as if they were experiencing an acute angioedema attack at
the time [26]. We feel that the use of VAS in retrospect is
competent, however, as stated earlier, the recall period is
rather long in our study.
Our study was not designed to evaluate the efficacy of
treatment in the AE subtypes. Interestingly, 79% of the
patients reported having not sought medical help in case
of an acute AE attack. This is remarkable given that 65%
of the patients rated their last attack as severe. Our
study was not designed to evaluate the reasons why pa-
tients are reluctant to seek medical advice in case of an
acute AE attack. However, one may speculate that pa-
tients with AE underestimate the severity and potential
consequences of their disease. We have made similar ob-
servations in food allergic patients [27].
We conclude that despite different etiologies, there are
strong clinical similarities among different subtypes of
non-HAE. Except for age, we did not find striking dif-
ferences between mast cell-mediated (AE with wheals
and idiopathic AE) and bradykinin-mediated AE (ACEi-
induced AE), with regards to dominant symptoms, pre-
ferred locations, and prodromal symptoms. These find-
ings support the previous suggestion that angioedema
resulting from bradykinin release and resulting from
mast cell mediator release show similar signs and
symptoms [2,11].
Further research should address the question whether
or not these subtypes of non-HAE share a final common
biochemical pathway leading to non-HAE since our
questionnaires were not designed to study this. Identifi-
cation of the molecular mechanisms of this pathway
may provide new targets for future intervention in all
non-HAE subtypes.
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